



ENZYMATIC THERAPY

What *Better* feels like™

January 16, 2006

Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 810
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

| PRODUCT NAME | STATEMENTS | INGREDIENT(S) TO WHICH THE CLAIM REFERS |
|----------------------------------|---|---|
| Cellular Forte™ Max ³ | When inositol combines with IP-6, they convert into two IP-3 molecules, which are essential for regulating healthy cell replication.* | Calcium (from calcium magnesium phytate), Phosphorus (from calcium magnesium phytate), Magnesium (from calcium magnesium phytate), IP-6 (inositol hexaphosphate) (from calcium magnesium phytate), Inositol, Maitake (Grifola frondosa) Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) (pentacyclic chemotype) Root Extract |

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: _____

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: _____

1-16-06

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

Michael P. Devereux
Chief Operations Officer

97S 0162

LET

17211

Cellular Forte Max3 c